Tango Therapeutics, Inc.

TNGX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
TNG260	Phase 2	Non Small Cell Lung Cancer	-
TNG462	Phase 2	Locally Advanced Solid Tumor	-
TNG456	Phase 2	Non Small Cell Lung Cancer	-
RMC-9805	Phase 2	PDAC	-
TNG908	Phase 2	Locally Advanced Solid Tumor	-

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

December 2025~TNG908

Primary completion for TNG908 trial (NCT05275478) in Locally Advanced Solid Tumor

Phase 2

January 2026~TNG260

Primary completion for TNG260 trial (NCT05887492) in Non Small Cell Lung Cancer

Phase 2

May 2026~TNG462

Primary completion for TNG462 trial (NCT05732831) in Locally Advanced Solid Tumor

Regulatory Approvals

TNGX News